Sutro Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Sutro Biopharma has a total shareholder equity of $98.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $403.4M and $305.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$313.22m |
Equity | US$98.02m |
Total liabilities | US$305.38m |
Total assets | US$403.40m |
Recent financial health updates
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Recent updates
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Financial Position Analysis
Short Term Liabilities: STRO's short term assets ($354.6M) exceed its short term liabilities ($79.5M).
Long Term Liabilities: STRO's short term assets ($354.6M) exceed its long term liabilities ($225.9M).
Debt to Equity History and Analysis
Debt Level: STRO is debt free.
Reducing Debt: STRO has no debt compared to 5 years ago when its debt to equity ratio was 10.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: STRO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.3% each year.